Hot Topics in Tech | August 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and blockchain technology industries. We have highlighted Illumina’s Q2 results and provided some insights about the company alongwith a quick run-through of the firm’s recent collaborations in China. Illumina reported a revenue of $830 million in Q2 which is a 25% increase compared to $662 million in the same quarter of 2017. Illumina’s biggest advantage over its competitors lies in its technology diversification. We have also discussed about Walmart, who aims to venture into transportation and logistics markets through a methodology (recently filed for patent) by

Continue reading »

Hot Topics in Tech | June 2018 Newsletter | Maxval

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and cloud-tech industries. We have talked about the FDA’s approval of tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.), a CD19-directed genetically modified autologous T-cell immunotherapy, to include treatment of patients with relapsed or refractory large B-cell lymphoma. Tisagenlecleucel is the only CAR T-cell therapy to receive FDA approval for two distinct indications. The report includes a chart of major commercial players in the CAR T-cell space and a Year-on-Year trend on the number of patents and patent applications from 2012 to 2018. We have

Continue reading »